X

FUROSEMIDE FRESENIUS KABI SOLUTION FOR INJECTION 20MG/2ML

Product Information

Registration Status: Active

SIN15131P

FUROSEMIDE FRESENIUS KABI SOLUTION FOR INJECTION 20MG/2ML is approved to be sold in Singapore with effective from 2016-12-07. It is marketed by FRESENIUS KABI (SINGAPORE) PTE LTD, with the registration number of SIN15131P.

This product contains Furosemide 20mg/2ml in the form of INJECTION, SOLUTION. It is approved for INTRAVENOUS use.

This product is manufactured by Labesfal - Laboratorios Almiro in PORTUGAL.

It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.

Product Reference
Loading...


Description

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for edema and chronic renal insufficiency. [PubChem]

Indication

For the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Also for the treatment of hypertension alone or in combination with other antihypertensive agents.

Mechanism of Action

Furosemide, a loop diuretic, inhibits water reabsorption in the nephron by blocking the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. This is achieved through competitive inhibition at the chloride binding site on the cotransporter, thus preventing the transport of sodium from the lumen of the loop of Henle into the basolateral interstitium. Consequently, the lumen becomes more hypertonic while the interstitium becomes less hypertonic, which in turn diminishes the osmotic gradient for water reabsorption throughout the nephron. Because the thick ascending limb is responsible for 25% of sodium reabsorption in the nephron, furosemide is a very potent diuretic.

Pharmacokinetics

Absorption
60% absorbed in patients with normal renal function
Distribution
Metabolism
Only a small amount is hepatically metabolized to the defurfurylated derivative, 4-chloro-5-sulfamoylanthranilic acid.
Elimination

Toxicity

Profound diuresis may cause fluid and electrolyte depletion. Excessive dehydration and potassium depletion may occur. Excessive diuresis may cause rapid weight loss, orthostatic hypotension or acute hypotensive episodes. May also cause tinnitus, reversible or permanent hearing loss or reversible deafness.

Active Ingredient/Synonyms

2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid | 4-Chloro-5-sulfamoyl-N-furfuryl-anthranilic acid | 4-Chloro-N-(2-furylmethyl)-5-sulfamoylanthranilic acid | 4-Chloro-N-furfuryl-5-sulfamoylanthranilic acid | Frusemide | Furosemid | Furosemida | Furosemide | Furosemidu | Furosemidum | Lasix (tn) | Furosemide |


Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.

References

  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank

Pharmfair.com uses cookies to improve your browsing experience. We'll assume you're ok with this, but you can opt-out if you wish. Peace!